Accès ouvert
2025
article
OpenAlex
Louis Carmarans, Claude Somma, Victoria RAMDOUR, Olivier Durieux et autres
BACKGROUND: How selective internal radiation therapy (SIRT) with personalized dosimetry fits with intermediate and advanced hepatocellular carcinoma (HCC) treatment remains unclear. The aims of our study were to investigate the efficacy and safety of SIRT in real-life settings within a nonsurgical HCC …
fr
(code pays fourni par la source)
Accès ouvert
2024
conference-abstract
OpenAlex
Alexia Gonzalez, Ana Laura Varela Constantino, Nereida Méndez‐Ramírez, Fernando J Medina-Olivares et autres
Background Myeloablative conditioning (MAC) is considered standard for fit persons with acute lymphoblastic leukemia (ALL) undergoing allogeneic transplantation (allo-HCT). Next generation flow cytometry allows for the detection of persons without measurable residual disease (MRD) who may not need MAC. Since 2019 Reduced-intensity …
mx
(code pays fourni par la source)
2024
conference-abstract
OpenAlex
Yadith Karina López‐García, Fernando De La Garza, Francisco Rubio, Alexia Gonzalez et autres
Introduction: Acute myeloid leukemia (AML) is a heterogeneous disease that can express more than one phenotypically distinct clone at diagnosis and during its evolution. Venetoclax, a BCL-2 inhibitor, along with azacitidine has been proposed as a therapeutic option. There are reports suggesting …
mx
(code pays fourni par la source)
2024
conference-abstract
OpenAlex
Alexia Gonzalez, Héctor Alejandro Vaquera Alfaro, Dalila Marisol Alvarado‐Navarro, Perla Rocío Colunga-Pedraza et autres
Background Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) from related donors has become more accessible due to difficulties in finding matched related donors, the high cost of matched unrelated donors (MUD), and the use of post-transplant cyclophosphamide (PTcy) to reduce acute graft-versus-host disease …
mx
(code pays fourni par la source)
2024
article
OpenAlex
Xavier Adhoute, Alexia Gonzalez, Thomas Lévi‐Strauss, Laurent Mineur et autres
BACKGROUND AND AIMS: The combination of atezolizumab plus bevacizumab (Atz/Bev) has radically changed the treatment strategy for advanced hepatocellular carcinoma (HCC) but raises questions. Our objectives were to determine survival outcomes and safety in a real-life multicenter French cohort, to investigate the …
fr
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
María Buti, Alexia Gonzalez, Mar Riveiro‐Barciela, Marc Bourlière
Hepatitis D virus was first described by Mario Rizzeto in 1977, and it is considered chronic viral hepatitis with the poorest prognosis. Despite its discovery almost 50 years ago, progress in its diagnosis and treatment has been scarce until recent years. The …
es, fr
(code pays fourni par la source)